Lyra therapeutics reports fourth quarter and full year 2022 financial results and provides corporate update

-- enlighten i pivotal phase 3 trial of lyr-210 in pre-surgical chronic rhinosinusitis (crs) on track to complete enrollment in mid-2023 -- -- data from beacon phase 2 trial of lyr-220 in post-surgical crs anticipated q4 2023 --
LYRA Ratings Summary
LYRA Quant Ranking